QC
CMPX icon

Quadrature Capital’s Compass Therapeutics CMPX Stock Holding History

Quadrature Capital’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.2K Buy
13,845
+1,552
+13% +$8.96K ﹤0.01% 1260
2025
Q4 		$66K Sell
12,293
-35,134
-74% -$162K ﹤0.01% 1146
2025
Q3 		$166K Buy
+47,427
New +$150K ﹤0.01% 812

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Quadrature Capital's CMPX Position: Q1 2026 in Review

Quadrature Capital increased its Compass Therapeutics (CMPX) stake by 13% in Q1 2026, buying an estimated $8.96K and bringing the position to 13,845 shares worth $73.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1260.

Quadrature Capital first reported a position in CMPX in Q3 2025 and has held it in 3 quarters since. The position peaked at $166K in Q3 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Quadrature Capital held 13,845 shares of Compass Therapeutics worth $73.2K as of Q1 2026.
  • Quadrature Capital bought 1,552 Compass Therapeutics shares in Q1 2026, an estimated $8.96K.
  • Compass Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1260 holding.
  • Quadrature Capital first reported a position in Compass Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Quadrature Capital's Compass Therapeutics position peaked at $166K in Q3 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.